VF
GANX icon

Virtu Financial’s Gain Therapeutics GANX Stock Holding History

Virtu Financial’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21K Buy
+10,685
New +$23.3K ﹤0.01% 1391
2025
Q4 		– Sell
-54,008
Closed -$96K – 1847
2025
Q3 		$96K Buy
54,008
+30,207
+127% +$51K 0.01% 1049
2025
Q2 		$43K Buy
+23,801
New +$44K ﹤0.01% 1162
2024
Q3 		– Sell
-27,356
Closed -$35K – 1546
2024
Q2 		$35K Buy
+27,356
New +$71K ﹤0.01% 954

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Virtu Financial's GANX Position: Q1 2026 in Review

Virtu Financial opened a new position in Gain Therapeutics (GANX) in Q1 2026: 10,685 shares worth $21K. The stake represents ﹤0.01% of the portfolio and ranks #1391 among its holdings. This is a return to the name: Virtu Financial previously reported a position in GANX as recently as Q3 2025.

Virtu Financial first reported a position in GANX in Q2 2024 and has held it in 4 quarters since. The position peaked at $96K in Q3 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Virtu Financial held 10,685 shares of Gain Therapeutics worth $21K as of Q1 2026.
  • Gain Therapeutics was a new Virtu Financial position in Q1 2026.
  • Gain Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1391 holding.
  • Virtu Financial first reported a position in Gain Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Virtu Financial's Gain Therapeutics position peaked at $96K in Q3 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.